Psoriatic arthritis

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

(Redirected from Psoriatic arthropathy)
Jump to: navigation, search

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Phone:617-525-6884

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [3] Phone:617-525-7431

Overview

Psoriatic arthritis
Classification and external resources
Psoriatic arthritis. Note to asymmetrical and advanced articular deformations.
ICD-10 L40.5, M07.
ICD-9 696.0

Click here for The Heart in Psoriasis

WikiDoc Resources for

Psoriatic arthritis

Articles

Most recent articles on Psoriatic arthritis

Most cited articles on Psoriatic arthritis

Review articles on Psoriatic arthritis

Articles on Psoriatic arthritis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Psoriatic arthritis

Images of Psoriatic arthritis

Photos of Psoriatic arthritis

Podcasts & MP3s on Psoriatic arthritis

Videos on Psoriatic arthritis

Evidence Based Medicine

Cochrane Collaboration on Psoriatic arthritis

Bandolier on Psoriatic arthritis

TRIP on Psoriatic arthritis

Clinical Trials

Ongoing Trials on Psoriatic arthritis at Clinical Trials.gov

Trial results on Psoriatic arthritis

Clinical Trials on Psoriatic arthritis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Psoriatic arthritis

NICE Guidance on Psoriatic arthritis

NHS PRODIGY Guidance

FDA on Psoriatic arthritis

CDC on Psoriatic arthritis

Books

Books on Psoriatic arthritis

News

Psoriatic arthritis in the news

Be alerted to news on Psoriatic arthritis

News trends on Psoriatic arthritis

Commentary

Blogs on Psoriatic arthritis

Definitions

Definitions of Psoriatic arthritis

Patient Resources / Community

Patient resources on Psoriatic arthritis

Discussion groups on Psoriatic arthritis

Patient Handouts on Psoriatic arthritis

Directions to Hospitals Treating Psoriatic arthritis

Risk calculators and risk factors for Psoriatic arthritis

Healthcare Provider Resources

Symptoms of Psoriatic arthritis

Causes & Risk Factors for Psoriatic arthritis

Diagnostic studies for Psoriatic arthritis

Treatment of Psoriatic arthritis

Continuing Medical Education (CME)

CME Programs on Psoriatic arthritis

International

Psoriatic arthritis en Espanol

Psoriatic arthritis en Francais

Businness

Psoriatic arthritis in the Marketplace

Patents on Psoriatic arthritis

Experimental / Informatics

List of terms related to Psoriatic arthritis

Psoriatic arthritis (also arthropathic psoriasis or psoriatic arthropathy)) is a type of inflammatory arthritis that affects around 5-7% (according to Oxford Handbook of Clinical Medicine) of people suffering from the chronic skin condition psoriasis. Psoriatic arthritis is said to be a seronegative spondyloarthropathy and therefore occurs more commonly in patients with tissue type HLA-B27. Treatment of psoriatic arthritis is similar to that of rheumatoid arthritis. More than 80% of patients with psoriatic arthritis will have psoriatic nail lesions characterised by pitting of the nails, or more extremely, loss of the nail itself (onycholysis).

Psoriatic arthritis can develop at any age, however on average it tends to appear about 10 years after the first signs of psoriasis. For the majority of people this is between the ages of 30 and 50, but it can also affect children. Men and women are equally affected by this condition. In about one in seven cases the arthritis symptoms may occur before any skin involvement.

As well as causing joint inflammation, psoriatic arthritis can cause tendinitis and a sausage-like swelling of the digits known as dactilytis. Radiology will give the appearance of "fluffy, new" bone.

Types of psoriatic arthritis

There are five main types of psoriatic arthritis:

  • Symmetric: This type accounts for around 50% of cases, and affects joints on both sides of the body simultaneously. This type is most similar to Rheumatoid arthritis and is disabling in around 50% of all cases.
  • Asymmetric: This type affects around 35% of patients and is generally mild. This type does not occur in the same joints on both sides of the body and usually only involves less than 3 joints.
  • Arthritis mutilans (M07.1): Affects less than 5% of patients and is a severe, deforming and destructive arthritis. This condition can progress over months or years causing severe joint damage.
  • Spondylitis (M07.2): This type is characterised by stiffness of the spine or neck, but can also affect the hands and feet, in a similar fashion to symmetric arthritis.
  • Distal interphalangeal predominant (M07.0): This type of psoriatic arthritis is found in about 5% of patients, and is characterised by inflammation and stiffness in the joints nearest to the ends of the fingers and toes. Nail changes are often marked.

Diagnosis

Radiographs of the hands demonstrate psoriatic arthritis

Treatments

The underlying process in psoriatic arthritis is inflammation, therefore treatments are directed at reducing and controlling inflammation. NSAIDs such as diclofenac and naproxen are usually the first line medication.

Other treatment options for this disease include joint injections with corticosteroids - this is only practical if a few joints are affected.

If acceptable control is not achieved using NSAIDs or joint injections then second line treatments with immunosuppressants such as methotrexate are added to the treatment regimen. An advantage of immunosuppressive treatment is that it also treats the psoriasis in addition to the arthropathy.

Recently, a new class of therapeutics developed using recombinant DNA technology called Tumor necrosis factor-alpha inhibitors have come available, for example, infliximab, etanercept, and adalimumab. These are becoming increasingly commonly used but are usually reserved for the most severe cases. As more is learned regarding the long-term safety of these biologic agents there is a trend toward earlier use to prevent irreversible joint destruction.

External links

de:Psoriasis-Arthritis

fr:Psoriasis#Arthrite psoriatique no:Psoriasis artritt

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
related articles
In other languages